0001558370-22-006858.txt : 20220503 0001558370-22-006858.hdr.sgml : 20220503 20220503171823 ACCESSION NUMBER: 0001558370-22-006858 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220404 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220503 DATE AS OF CHANGE: 20220503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiromic Biopharma, Inc. CENTRAL INDEX KEY: 0001792581 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464762913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39619 FILM NUMBER: 22888343 BUSINESS ADDRESS: STREET 1: 7707 FANNIN ST. STREET 2: SUITE 140 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 832-968-4888 MAIL ADDRESS: STREET 1: 7707 FANNIN ST. STREET 2: SUITE 140 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: Kiromic, Inc. DATE OF NAME CHANGE: 20191029 8-K 1 krbp-20220404x8k.htm 8-K
0001792581false00017925812022-04-042022-04-04

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 4, 2022

Kiromic BioPharma, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

Delaware

    

001-39619

    

46-4762913

(State or other jurisdiction
of incorporation)

​

(Commission
File Number)

​

(IRS Employer
Identification No.)

​

, TX,

​

​

7707 Fannin, Suite 140

Houston, TX,

77054

(Address of principal executive offices)

(Zip Code)

​

Registrant’s telephone number, including area code (832) 968-4888

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

Title of Each Class

​

Trading Symbol(s)

​

Name of Each Exchange on Which Registered

Common Stock, $0.001 par value

​

KRBP

​

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 4.01 Changes in Registrant’s Certifying Accountant.

Engagement of New Independent Registered Public Accounting Firm

On April 29, 2022, the Audit Committee of the Board of Directors of Kiromic BioPharma, Inc. (the “Company”) notified Whitley Penn LLP (“Whitley Penn”) that Whitley Penn had been approved as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.

​

On April 29, 2022, the Company and Whitley Penn executed an engagement letter formally engaging Whitley Penn as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.

​

During the fiscal years ended December 31, 2021 and 2020 and the subsequent interim period through the filing of this Current Report on Form 8-K, the Company did not consult with Whitley Penn with respect to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the Company’s financial statements, and no written report or oral advice was provided to the Company by Whitley Penn that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was subject to any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

​

Departure of Independent Registered Public Accounting Firm

On April 4, 2022, Deloitte & Touche LLP (“Deloitte”) advised the Company’s Audit Committee that it would not stand for reappointment as the Company’s independent registered public accounting firm. Deloitte will no longer serve as the Company’s independent registered accounting firm following the completion by Deloitte of its services as the Company’s independent registered public accounting firm for the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. The Company has requested that Deloitte respond fully to the inquiries of Whitley Penn, the Company’s successor independent registered public accounting firm, and Deloitte has agreed to cooperate with the Company and Whitley Penn with respect to the transition.

​

During the Company’s fiscal years ended December 31, 2021 and 2020 and the subsequent interim period through the filing of this Current Report on Form 8-K, there were no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) with Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Deloitte, would have caused Deloitte to make reference to the subject matter of such disagreements in connection with its report.

​

Deloitte’s report on the consolidated financial statements for the Company’s fiscal years ended December 31, 2021 and 2020 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that Deloitte’s report for the years ended December 31, 2021 and 2020 contained an explanatory paragraph indicating that there was substantial doubt about the ability of the Company to continue as a going concern.

​

During the Company’s fiscal years ended December 31, 2021 and 2020 and the subsequent interim period through the filing of this Current Report on Form 8-K , there have been no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K), except for certain material weaknesses in the Company’s internal control over financial reporting. As previously disclosed in Part II, Item 9A, "Controls and Procedures," of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, the Company identified material weaknesses resulting from (a) the Company’s lack of internal control processes and procedures regarding the financial close and reporting process, procure to pay process, and human resources and payroll process, (b) those controls being designed without the appropriate segregation of duties; and (c) the Company’s lack of full-time accounting and finance personnel. As previously disclosed in Part II, Item 9A, "Controls and Procedures," of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, in addition to the material weaknesses resulting from the causes described in items (a) through (c) in the preceding sentence, the Company identified material weaknesses resulting from the Company’s internal communication deficiencies

​

surrounding the Company’s failure to timely disclose certain communications from the FDA received on June 16 and 17, 2021.

​

The Company provided Deloitte with a copy of the disclosure contained in this Current Report on Form 8-K and requested that Deloitte furnish the Company with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether Deloitte agrees with the statements contained in this Current Report on Form 8-K.  Deloitte has provided the Company with a letter addressed to the SEC stating whether it agrees with the above statements, a copy of which is filed as Exhibit 16.1 herewith.

Item 9.01    Financial Statements and Exhibits.

(d)  Exhibits.

​

The following documents are herewith filed or furnished as exhibits to this report:

​

​

Exhibit No.

    

Description

​

​

​

16.1

​

Letter of Deloitte & Touche LLP dated May 3, 2022.

​

​

​

​

​

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 3, 2022

 

​

 

KIROMIC BIOPHARMA, INC.

​

​

​

​

​

 

​

 

By:

 

/s/ Daniel Clark

​

 

​

 

​

 

Name: Daniel Clark

Title: Interim Chief Financial Officer

​

 

​

 

​

 

​

​

​

​

- 4 -

 EX-16.1 2 krbp-20220404xex16d1.htm EX-16.1 Form 1362S

​

Bagby St. Suite 4500

TX, 77002 USA

​

+1 (713) 982-4077

​

​

Graphic

Deloitte & Touche LLP

1111 Bagby St. Suite 4500

Houston, TX, 77002 USA

​

Tel: +1 (713) 982-4077

www.deloitte.com

​

May 3, 2022

​

Securities and Exchange Commission 100 F Street, N.E.

Washington, D.C. 20549-7561 Dear Sirs/Madams:

We have read Item 4.01 of Kiromic BioPharma, Inc’s Form 8-K dated May 3, 2022, and have the following comments:

​

1.We agree with the statements made in the section titled “Departure of

Independent Registered Public Accounting Firm”.

​

2.We have no basis on which to agree or disagree with the statements made in

the section titled “Engagement of New Independent Registered Public

Accounting Firm”.

Yours truly,

​

/s/ Deloitte & Touche LLP

 GRAPHIC 3 krbp-20220404xex16d1001.jpg GRAPHIC begin 644 krbp-20220404xex16d1001.jpg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end EX-101.SCH 4 krbp-20220404.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 krbp-20220404_lab.xml EX-101.LAB EX-101.PRE 6 krbp-20220404_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 04, 2022
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Apr. 04, 2022
Entity Registrant Name Kiromic BioPharma, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39619
Entity Tax Identification Number 46-4762913
Entity Address, Address Line One 7707 Fannin
Entity Address, Adress Line Two Suite 140
Entity Address, City or Town Houston
Entity Address State Or Province TX
Entity Address, Postal Zip Code 77054
City Area Code 832
Local Phone Number 968-4888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol KRBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001792581
Amendment Flag false
XML 8 krbp-20220404x8k_htm.xml IDEA: XBRL DOCUMENT 0001792581 2022-04-04 2022-04-04 0001792581 false 8-K 2022-04-04 Kiromic BioPharma, Inc. DE 001-39619 46-4762913 7707 Fannin Suite 140 Houston TX 77054 832 968-4888 false false false false Common Stock, $0.001 par value KRBP NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

*HU0<.&7J/P$ #P" / M " 6\0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !' MBJ-4)!Z;HJT #X 0 &@ @ ';$0 >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !'BJ-499!YDAD! #/ P $P M @ ' $@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" *% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.kiromic.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports krbp-20220404x8k.htm krbp-20220404.xsd krbp-20220404_lab.xml krbp-20220404_pre.xml krbp-20220404xex16d1.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "krbp-20220404x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "krbp-20220404x8k.htm" ] }, "labelLink": { "local": [ "krbp-20220404_lab.xml" ] }, "presentationLink": { "local": [ "krbp-20220404_pre.xml" ] }, "schema": { "local": [ "krbp-20220404.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "krbp", "nsuri": "http://www.kiromic.com/20220404", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "krbp-20220404x8k.htm", "contextRef": "Duration_4_4_2022_To_4_4_2022_hmWfKjWBbUetv4RCudfKrA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "krbp-20220404x8k.htm", "contextRef": "Duration_4_4_2022_To_4_4_2022_hmWfKjWBbUetv4RCudfKrA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kiromic.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001558370-22-006858-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-006858-xbrl.zip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end